James J. Schlesselman, PhD
Professor, Department of Biostatistics
Director, Biostatistics Facility UPCI
Education BS, Michigan State University, 1966
MA (Psychology), Princeton University, 1968
MA (Statistics), Princeton University, 1968
PhD (Statistics), Princeton University, 1971 Research Interests Role of statistics in scientific inference. Statistical methods for planning and analyzing controlled clinical trials and epidemiologic studies. Current Committees University of Pittsburgh Cancer Institute Clinical Research Oversight Committee, 2004 - present
Clinical Research Committee, 2005 - present
Data and Safety Monitoring Committee, 2004 - present
Independent Data and Safety Monitoring Committee, 2004 - present
Protocol Review Committee B, 2004 - present National Institute on Drug Abuse (NIDA) Data and Safety Monitoring Board for NIDA's National Drug Abuse Treatment Clinical Trials Network (CTN). Member, April 2005 – present.
Books
Schlesselman, JJ. Case-Control Studies: Design, Conduct, Analysis . New York : Oxford University Press, 1982, xv + 354 pp. (in Japanese translation, 1985) Selected Publications Schlesselman JJ, Reis IM. Phase II clinical trials in oncology: strengths and limitations of two-stage designs. Cancer Invest . 2006 Jun-Jul;24(4):404-12. Singal R, Das PM, Manoharan M, Reis IM, Schlesselman JJ. Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep 2005; 14: 569-73. Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncology 2004; 25: 1465-71. Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and relationship with clinicopathological features of disease. Oncol Reports 2004; 12: 631-7. Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER. Allogeneic vaccination with a B7.1 (CD80) and HLA A gene modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22: 2800-7. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with hormonal contraception. Am J Obstet Gynecol 2004;190:S5-22. Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Induction of CD8 T-cell-Ifn-? response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Therapy 2003; 10:850-8. Schlesselman JJ, Collins JA. Evaluating systematic reviews and meta-analyses. Seminars in Reproductive Medicine 2003; 21:95-105. Sofer M, Hamilton-Nelson KL, Schlesselman JJ, Soloway MS. Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy. J Clin Oncol 2002; 20:1853-58 . Walker GR, Schlesselman JJ, Ness RB. Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 2002; 186:8-14. Collins JA, Schlesselman JJ. Perimenopausal use of reproductive hormones: effects on breast and endometrial cancer . Obstet Gynecol Clin North Am 2002; 29:511-25. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, Morgan M, Wheeler JE, and the SHARE Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol 2000;152:233-241. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-117. Collins JA, Schlesselman JJ. Hormone replacement therapy and endometrial cancer. In Lobo R ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 2nd editio n. New York : Lippincott-Raven, 1999: 503-511. Contact Information Suite 325 Sterling Plaza
201 North Craig Street
Pittsburgh, PA 15213
Telephone: 412-383-1541
Facsimile: 412-383-1535
Email: jjs@upci.pitt.edu | 
